Last updated on October 2010

Safety and Immunogenicity Study of the Tetravalent Rotavirus Vaccine


Brief description of study

A double blind placebo controlled Phase I/II study to evaluate the safety and immunogenicity of the Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]in Indian infants. The study would be carried out in 90 healthy infants. Three doses of the rotavirus vaccine or placebo would be administered orally to each infant at 6-8, 10-12 and 14-16 weeks of age. The rotavirus vaccine would be administered at one of the two planned virus concentrations (10e5.5 or 10e6.25 FFU of each constituent serotype per 0.5 ml). Each administration of the vaccine/placebo would be preceded by oral administration of 2.0 mL of antacid.

Clinical Study Identifier: NCT01061658

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Gagandeep Kang, MD PhD

Christian Medical College
Vellore, India
  Connect »